Cytosorbents (NASDAQ:CTSO) Earns Buy Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued to investors on Monday morning,Benzinga reports. They currently have a $10.00 price objective on the medical research company’s stock.

A number of other equities analysts also recently issued reports on CTSO. HC Wainwright reissued a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a research note on Monday, November 11th. StockNews.com assumed coverage on shares of Cytosorbents in a research note on Monday. They issued a “hold” rating for the company. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Stock Performance

NASDAQ CTSO opened at $1.05 on Monday. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The company has a 50-day simple moving average of $0.92 and a two-hundred day simple moving average of $1.03. The firm has a market cap of $57.41 million, a price-to-earnings ratio of -2.92 and a beta of 0.58. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $1.59.

Institutional Investors Weigh In On Cytosorbents

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its position in shares of Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the period. Sargent Investment Group LLC increased its holdings in Cytosorbents by 13.4% in the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after acquiring an additional 192,747 shares during the last quarter. Finally, Atomi Financial Group Inc. bought a new stake in Cytosorbents in the 3rd quarter valued at $51,000. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.